Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;77(11):1131-1139.
doi: 10.1136/thoraxjnl-2021-217190. Epub 2021 Dec 22.

Respiratory symptoms and lung function in patients treated for pulmonary tuberculosis in Malawi: a prospective cohort study

Affiliations

Respiratory symptoms and lung function in patients treated for pulmonary tuberculosis in Malawi: a prospective cohort study

Rebecca Nightingale et al. Thorax. 2022 Nov.

Abstract

Rationale: Pulmonary tuberculosis (PTB) can cause post-TB lung disease (PTLD) associated with respiratory symptoms, spirometric and radiological abnormalities. Understanding of the predictors and natural history of PTLD is limited.

Objectives: To describe the symptoms and lung function of Malawian adults up to 3 years following PTB-treatment completion, and to determine the evolution of PTLD over this period.

Methods: Adults successfully completing PTB treatment in Blantyre, Malawi were followed up for 3 years and assessed using questionnaires, post-bronchodilator spirometry, 6 min walk tests, chest X-ray and high-resolution CT. Predictors of lung function at 3 years were identified by mixed effects regression modelling.

Measurement and main results: We recruited 405 participants of whom 301 completed 3 years follow-up (mean (SD) age 35 years (10.2); 66.6% males; 60.4% HIV-positive). At 3 years, 59/301 (19.6%) reported respiratory symptoms and 76/272 (27.9%) had abnormal spirometry. The proportions with low FVC fell from 57/285 (20.0%) at TB treatment completion to 33/272 (12.1%), while obstruction increased from and 41/285 (14.4%) to 43/272 (15.8%) at 3 years. Absolute FEV1 and FVC increased by mean 0.03 L and 0.1 L over this period, but FEV1 decline of more than 0.1 L was seen in 73/246 (29.7%). Higher spirometry values at 3 years were associated with higher body mass index and HIV coinfection at TB-treatment completion.

Conclusion: Spirometric measures improved over the 3 years following treatment, mostly in the first year. However, a third of PTB survivors experienced ongoing respiratory symptoms and abnormal spirometry (with accelerated FEV1 decline). Effective interventions are needed to improve the care of this group of patients.

Keywords: tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Participant flow diagram.
Figure 2
Figure 2
(A) FEV1 z-score change (non-normalised individual intervals). (B) FVC z-score change (non-normalised individual intervals). (C) Sankey plot showing change of spirometry pattern (using GLI and LLN in those who completed ATS standard spirometry) between each visit from TB treatment completion to the final 3-year visit. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Figure 3
Figure 3
Coefficient estimates (95% CI) for multivariable regression models with Z-score change in spirometry values in the 3-year follow-up period after TB treatment completion as the outcome and different covariate sets. FEV, forced expiratory volume; FVC, forced vital capacity; SES, socioeconomic status.

References

    1. WHO . Global tuberculosis report, 2019. Geneve, Switzerland: World Health Organisation, 2019. https://www.who.int/tb/publications/global_report/en/
    1. WHO . Malawi WHO fact sheet, 2017. Available: http://www.who.int/countries/mwi/en/
    1. van Kampen SC, Wanner A, Edwards M, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Health 2018;3:e000745. 10.1136/bmjgh-2018-000745 - DOI - PMC - PubMed
    1. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. The Lancet 2021;397:928–40. 10.1016/S0140-6736(21)00458-X - DOI - PubMed
    1. Meghji J, Lesosky M, Joekes E, et al. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study. Thorax 2020;75:269–78. 10.1136/thoraxjnl-2019-213808 - DOI - PMC - PubMed

Publication types

Substances